Federica Giugliano, MD, Gustave Roussy Cancer Center, Villejuif, France, highlights the need for increased BRCA-1 mutant screening in older patients with triple-negative breast cancer (TNBC). Whilst the KEYNOTE-522 (NCT03036488) based guidelines are not being updated to account for this, it is essential in the majority of TNBC cases because it is a targeted alteration that has the potential to change the course of treatment, as seen in Dr Giugliano’s case study presented at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, during which this interview took place.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
